DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Muhammad A, van der Lely AJ, Janssen J, Neggers S.
Efficacy and safety of switching to pasireotide LAR alone or in combination with pegvisomant in acromegaly patients controlled with combination treatment of first-generation somatostatin analogues and weekly pegvisomant (PAPE study): a prospective open-label 48 week study, preliminary results 24 weeks.
Endocr Abst.
2017;
DOI: 10.1530/endoabs.49.gp174:.
Access:
We do not assume any responsibility for the contents of the web pages of other providers.